Imfinzi Approved in EU for Extensive-stage Small Cell Lung Cancer
Imfinzi Approved in EU for Extensive-stage Small Cell Lung Cancer The European Commission has approved a combination of Imfinzi (durvalumab) plus standard chemotherapy as a first-line treatment for people with extensive-stage small cell lung cancer (SCLC). Findings from the CASPIAN Phase 3 trial (NCT03043872) supported the decision. There, newly diagnosed patients with extensive-stage (widely spread) […]
Read More